Company intelligence / Profile preview

Nanopath

Cambridge, Massachusetts, USA

Ownership: Private
Employees: ~26
Development stage: Other

Overview

Nanopath’s platform enables rapid, multiplexed point-of-care detection of infectious pathogens causing women’s pelvic and gynecologic infections, providing high-specificity results in under 20 minutes; the platform has won major industry awards and is being piloted for clinical implementation

Therapeutic areas: Infectious DiseasesWomen's Health
Modalities: DeviceNanoparticle (the core technology is a nanobiosensing platform)
Industry: Molecular Diagnostics

Partnerships

Dartmouth Hitchcock Medical Center (academic, clinical collaboration)

Beyond the preview

Go deeper on Nanopath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanopath.

Explore the full profile